The biotech sector must not only maintain an emphasis on ground-breaking products and focus on retaining key staff but also mobilize to ensure that US health policy continues to reward its innovations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reinhardt, U.E. Health Aff. 20, 136–149 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scangos, G. Proceeding in a receding economy. Nat Biotechnol 27, 424–425 (2009). https://doi.org/10.1038/nbt0509-424
Issue Date:
DOI: https://doi.org/10.1038/nbt0509-424
This article is cited by
-
Healthcare-biotech symbiosis
Nature Biotechnology (2009)